Скачать или смотреть What's The Buzz On Cipla And Sun Pharma | ET Now

Cipla Received 6 observations from USFDA inspection at Goa manufacturing facility. Some observations were repeat observations of August 2019 inspections. There were no data integrity observations reported. 81% of total 43 analysts have buy-rating as per Bloomberg for Cipla. BoFA has maintained a buy rating with a target price at Rs 1,030 per share. Specialty driven earning story in Sun Pharma has wider recognition and is the likely catalyst for the next leg-up on the stock. Upside to existing specialty portfolio that can be augmented by new additions. However, the brokerage stated that there is skepticism in Ilumya ramp-up despite upside risk.

#cipla #sunpharma #etnow
Subscribe To ET Now For Latest Updates On Stocks, Business, Trading | ► https://goo.gl/SEjvK3

Subscribe Now To Our Network Channels :-
Times Now : http://goo.gl/U9ibPb
The NewsHour Debate : http://goo.gl/LfNgFF

To Stay Updated Download the Times Now App :-
Android Google Play : https://goo.gl/zJhWjC
Apple App Store : https://goo.gl/d7QBQZ

Social Media Links :-
Twitter - http://goo.gl/hA0vDt
Facebook - http://goo.gl/5Lr4mC
G+ - http://goo.gl/hYxrmj
Website - www.etnownews.com